OCULAR THERAPEUTIX INC
OCULNASDAQTrading Snapshot
- Day Range
- $9.65 – $9.84
- 52-Week Range
- $6.23 – $16.44
- Volume
- $2.70B
- Avg Volume
- $2.20B
- Shares Outstanding
- 219.0M
- Next Earnings
- Sep 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $52M
- Last Q Revenue
- $12M
- P/E Ratio
- —
- P/S Ratio
- 38.8x
- EPS (TTM)
- $-1.41
- Dividend Yield
- —
Why Investors Own OCUL
- ✓High-growth profile — revenue up -8.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About OCULAR THERAPEUTIX INC
A company profile for OCULAR THERAPEUTIX INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat
Ocular Therapeutix eyes a 2027 AXPAXLI launch for wet AMD/retinal disease with strong Phase 3 data, an FDA-aligned NDA in Q4 2026. Click here to read more.
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of $(0.39) per share
Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?
Ocular Therapeutix (OCUL) has drawn investor attention after recent trading saw the stock close at $8.62, with returns under pressure over the past month and past 3 months despite positive annual revenue growth. See our latest analysis for Ocular Therapeutix. Over a longer horizon, Ocular Therapeutix’s share price has come under pressure, with the year to date share price return down 27.07%, while the 3 year total shareholder return is up 100%. This points to strong historical swings in...
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on
3 Cash-Burning Stocks with Open Questions
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.